세계의 미세잔존질환 검사 시장 예측(-2029년) : 제품별, 기술별, 용도별, 최종사용자별, 지역별

The MRD testing market will rise in value from estimated USD 1.43 Billion in 2024 to USD 2.55 Billion in 2029, at a CAGR of 12.2% over the forecast period. Increased funding and grants for cancer control programs across the globe have emerged as an important growth factor in the MRD testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of cancer, especially in terms of early detection and prevention. These funds are being channelled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of cancer. Apart from that, research grants and international collaborations are also enabling cancer testing integration into routine health care services. Thus, this growing funding is rendering MRD tests available and enhancing the efforts to control cancer globally. This, in turn, is fuelling the growth of the global minimal residual disease testing market.

"MRD Assay Kits & Reagents segment is expected to have the fastest growth rate in the MRD testing market, by product, during the forecast period."

The MRD testing market is segmented into assay kits & reagents, and instruments based on product. Assay kits & reagents are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy of tests. Growing penetration of these tests in high-risk populations, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in cancer and advancements in diagnostics are also driving the high growth of the test kits segment in the MRD testing market.

"Haematological malignancies segment accounted for the highest growth rate in the MRD testing market, by application, during the forecast period."

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.

"Asia Pacific: The fastest-growing region in MRD testing market."

The worldwide market for MRD testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drives the need for essential cancer screening and management. Growth in government and international organization funding and campaigns against cancer has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of cancer has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the MRD testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the MRD testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the MRD testing market:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: Managers - 30%, D-level - 50%, and Others - 20%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Others - 4%

The key players in this market are are F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China).

Research Coverage:

This research report categorizes the MRD testing market by product (assay kits & reagents, instruments), by technology (PCR, NGS, flow cytometry, and other applications), by application (hematological malignancies, solid tumors, multiple myeloma, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the MRD testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the MRD testing market. Competitive analysis of upcoming startups in the MRD testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall MRD testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising incidence of cancer, and increased funding and grants for cancer control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the MRD testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the MRD testing market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the MRD testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the MRD testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ESTIMATION
• 2.6 STUDY ASSUMPTIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RESEARCH LIMITATIONS
• 2.9 RISK ASSESSMENT
  • 2.9.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
• 4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY PRODUCT, 2024 VS. 2029
• 4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029
• 4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2024 VS. 2029
• 4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2024 VS. 2029
• 4.6 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of hematological malignancies
    • 5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
    • 5.2.1.3 Increasing cancer awareness initiatives by global health organizations
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complex regulatory frameworks delaying approvals of new molecular diagnostics tests
    • 5.2.2.2 High cost of minimal residual disease testing kits
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging countries
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Unclear reimbursement scenario and policies for patients
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING TREND OF KEY PLAYERS, BY PRODUCT & REGION
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA
  • 5.7.2 EXPORT DATA
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 BUYING CRITERIA
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY LANDSCAPE
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
      • 5.11.1.4.2 Mexico
    • 5.11.1.5 Middle East
    • 5.11.1.6 Africa
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 PCR and NGS
  • 5.12.2 ADJACENT TECHNOLOGIES
    • 5.12.2.1 Digital PCR
• 5.13 KEY CONFERENCES & EVENTS IN 2023-2024
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
• 5.17 IMPACT OF AI/GEN AI ON MINIMAL RESIDUAL DISEASE TESTING MARKET

6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ASSAY KITS & REAGENTS
  • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO DRIVE MARKET GROWTH

7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 POLYMERASE CHAIN REACTION
  • 7.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
• 7.3 NEXT-GENERATION SEQUENCING
  • 7.3.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO SUPPORT ADOPTION
• 7.4 FLOW CYTOMETRY
  • 7.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
• 7.5 OTHER TECHNOLOGIES

8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 HEMATOLOGICAL MALIGNANCIES
  • 8.2.1 LEUKEMIA
    • 8.2.1.1 Myeloid leukemia
      • 8.2.1.1.1 High prevalence of AML in adults to support growth
    • 8.2.1.2 Lymphocytic leukemia
      • 8.2.1.2.1 High incidence of ALL in children to drive market
    • 8.2.1.3 Other leukemias
  • 8.2.2 LYMPHOMA
    • 8.2.2.1 Non-Hodgkin lymphoma
      • 8.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
    • 8.2.2.2 Hodgkin lymphoma
      • 8.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel demand for MRD testing
• 8.3 SOLID TUMORS
  • 8.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
• 8.4 MULTIPLE MYELOMA
  • 8.4.1 RISING INCIDENCE OF MULTIPLE MYELOMAS TO DRIVE MARKET
• 8.5 OTHER APPLICATIONS

9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & SPECIALTY CLINICS
  • 9.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
• 9.3 DIAGNOSTIC LABORATORIES
  • 9.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
• 9.4 ACADEMIC & RESEARCH INSTITUTES
  • 9.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
• 9.5 OTHER END USERS

10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Increasing prevalence of cancer to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Availability of various cancer screening programs to support market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Government support for research funding to support MRD testing market
  • 10.3.3 UK
    • 10.3.3.1 Increasing number of diagnostic laboratories to propel market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising R&D expenditure in France to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Favorable funding scenario to drive market
  • 10.3.6 SPAIN
    • 10.3.6.1 Consolidation of laboratories in Spain to support market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Growing public access to advanced healthcare facilities to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Universal healthcare reimbursement policy to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing private and public investments in healthcare system to drive market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
  • 10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE AND FUNDING IN RESEARCH TO DRIVE GCC MARKET
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 LIST OF EVALUATED VENDORS
  • 11.5.2 STARS
  • 11.5.3 EMERGING LEADERS
  • 11.5.4 PERVASIVE PLAYERS
  • 11.5.5 PARTICIPANTS
  • 11.5.6 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.6.1 Company footprint
    • 11.5.6.2 Product footprint
    • 11.5.6.3 Technology footprint
    • 11.5.6.4 Application footprint
    • 11.5.6.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 F. HOFFMANN-LA ROCHE AG
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 GUARDANT HEALTH, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches & approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 SYSMEX CORPORATION
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 NEOGENOMICS LABORATORIES
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 ADAPTIVE BIOTECHNOLOGIES
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 ARCHERDX (INVITAE CORPORATION)
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
      • 12.1.8.3.2 Deals
  • 12.1.9 BIO-RAD LABORATORIES, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 NATERA, INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 OPKO HEALTH, INC.
  • 12.2.2 GENETRON HEALTH
  • 12.2.3 QUEST DIAGNOSTICS, INC.
  • 12.2.4 ASURAGEN, INC.
  • 12.2.5 INVIVOSCRIBE, INC.
  • 12.2.6 ARUP LABORATORIES INC.
  • 12.2.7 MISSION BIO, INC.
  • 12.2.8 CERGENTIS B.V.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS